Current and potential imaging applications of ferumoxytol for magnetic resonance imaging.
Contrast-enhanced magnetic resonance imaging is a commonly used diagnostic tool. Compared with standard gadolinium-based contrast agents, ferumoxytol (Feraheme, AMAG Pharmaceuticals, Waltham, MA), used as an alternative contrast medium, is feasible in patients with impaired renal function. Other attractive imaging features of i.v. ferumoxytol include a prolonged blood pool phase and delayed intracellular uptake. With its unique pharmacologic, metabolic, and imaging properties, ferumoxytol may play a crucial role in future magnetic resonance imaging of the central nervous system, various organs outside the central nervous system, and the cardiovascular system. Preclinical and clinical studies have demonstrated the overall safety and effectiveness of this novel contrast agent, with rarely occurring anaphylactoid reactions. The purpose of this review is to describe the general and organ-specific properties of ferumoxytol, as well as the advantages and potential pitfalls associated with its use in magnetic resonance imaging. To more fully demonstrate the applications of ferumoxytol throughout the body, an imaging atlas was created and is available online as supplementary material.
Toth, GB; Varallyay, CG; Horvath, A; Bashir, MR; Choyke, PL; Daldrup-Link, HE; Dosa, E; Finn, JP; Gahramanov, S; Harisinghani, M; Macdougall, I; Neuwelt, A; Vasanawala, SS; Ambady, P; Barajas, R; Cetas, JS; Ciporen, J; DeLoughery, TJ; Doolittle, ND; Fu, R; Grinstead, J; Guimaraes, AR; Hamilton, BE; Li, X; McConnell, HL; Muldoon, LL; Nesbit, G; Netto, JP; Petterson, D; Rooney, WD; Schwartz, D; Szidonya, L; Neuwelt, EA
Volume / Issue
Start / End Page
Pubmed Central ID
Electronic International Standard Serial Number (EISSN)
Digital Object Identifier (DOI)